Recent Updates — IMRN
Immuron Limited filed a Form 6-K to report on its CEO Steven Lydeamore's presentation at the Coffee Microcaps Conference held in Sydney on September 22, 2026. The filing discloses FY2026 financial results showing global sales revenue of $7.7 million, up 6% year-over-year, with a net loss of $(3.8) million and cash reserves of A$9.0 million as of June 30, 2026. Key operational highlights include the completion of an n=851 Travelan trial, FDA approval for an IMM-529 IND application, and the execution of an exclusive U.S. distribution agreement in September 2026. The company announced a strategic reset to partner its clinical assets, IMM-124E and IMM-529, aiming to reduce cash burn and improve profitability through licensing deals while maintaining commercial operations for Travelan and ProIBS. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
Immuron Limited executed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the United States. PROIBS® is a medical device for abdominal pain and digestive issues containing AVH200®, derived from Aloe barbadensis Mill., which has been available in European markets for over a decade. The U.S. digestive health supplement market is valued at $4.16 billion, with Immuron targeting a specific subset. This agreement expands Immuron's commercial presence following the product's launch in Australia during FY26. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.
Immuron Limited reported preliminary results for the fiscal year ended June 30, 2026, with revenue increasing 5.9% to A$7.7 million and net loss narrowing by 26.4% to A$3.8 million. Cash reserves rose significantly to A$9.0 million from A$2.8 million the prior year, supported by a large equity raise via an At-the-Market facility that increased share count to over 322 million. The company achieved key clinical milestones, including FDA approval of its IND for IMM-529 and completion of the IMM-124E trial, while signing a U.S. Department of Defense research agreement. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.
Immuron Limited filed a Form 6-K to report that CEO Steven Lydeamore presented at the Emerging Growth Conference in Melbourne on August 19, 2026. The presentation highlighted FY2026 global sales revenue of A$7.7 million, up 6% year-over-year, with strong growth in Australia and the U.S. The company announced a strategic reset to partner its clinical assets IMM-124E and IMM-529 for development and commercialization to reduce cash burn and unlock value through licensing fees and milestones. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.